Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.523
Sell
RSI(14)
40.835
Neutral
STOCH(KDJ)(9,3,3)
16.914
Neutral
ATR(14)
1.061
Low Volatility
CCI(14)
-174.250
Sell
Williams %R
76.071
Sell
TRIX(12,20)
-0.463
Sell
StochRSI(14)
0.000
Oversold
Seres Therapeutics Inc
MCRB14.735USD
-0.245-1.64%
Market hours （ET）Quotes delayed by 15 min
129.15MMarket Cap
45.57P/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Seres Therapeutics Inc
Currency: USD Updated: 2025-12-19Key Insights
Seres Therapeutics Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 157/404 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 21.00.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Seres Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
3
analysts
Hold
Current Rating
21.000
Target Price
+22.24%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Seres Therapeutics Inc Highlights
StrengthsRisks
Seres Therapeutics, Inc. is a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics. It is developing SER-155, which has shown a significant reduction in bloodstream infections and related complications (as compared to placebo) in a Phase 1b clinical study in patients undergoing allo-HSCT and Fast Track designation to reduce the risk of infection and graft-versus-host disease in adults undergoing allo-HSCT. SER-155 and the Company’s other pipeline programs are designed to target multiple disease-relevant pathways. In addition to allo-HSCT, it intends to evaluate SER-155 and other cultivated live biotherapeutic candidates in other medically patient populations, including autologous-HSCT patients, cancer patients with neutropenia, CAR-T recipients, individuals with chronic liver disease, solid organ transplant recipients, as well as patients in the intensive care unit and long-term acute care facilities.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Overvalued
The company’s latest PE is 46.33, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 2.32M shares, decreasing 49.25% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 311.89K shares of this stock.
Financial Health
Currency: USD Updated: 2025-12-19The current financial score of Seres Therapeutics Inc is 8.58, ranking 42/404 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is high.
Score
Financials
7.66
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.45
Operational Efficiency
10.00
Growth Potential
10.00
Shareholder Returns
7.77
Seres Therapeutics Inc's Company Valuation
Currency: USD Updated: 2025-12-19The current valuation score of Seres Therapeutics Inc is 6.15, ranking 336/404 in the Biotechnology & Medical Research industry. Its current P/E ratio is 46.33, which is 2135.88% below the recent high of 1035.80 and 109.88% above the recent low of -4.58.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 157/404
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2025-12-19The current earnings forecast score of Seres Therapeutics Inc is 7.00, ranking 314/404 in the Biotechnology & Medical Research industry. The average price target for Seres Therapeutics Inc is 21.00, with a high of 22.00 and a low of 20.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
3
analysts
Hold
Current Rating
21.000
Target Price
+22.24%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
534
Total
6
Median
6
Average
Company name
Ratings
Analysts
Seres Therapeutics Inc
MCRB
3
CRISPR Therapeutics AG
CRSP
30
IQVIA Holdings Inc
IQV
25
argenx SE
ARGX
25
Intellia Therapeutics Inc
NTLA
25
Ionis Pharmaceuticals Inc
IONS
24
1
2
3
...
107
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2025-12-19The current price momentum score of Seres Therapeutics Inc is 5.01, ranking 350/404 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 18.84 and the support level at 12.57, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
15.560
Sell
MA10
16.284
Sell
MA20
16.767
Sell
MA50
17.400
Sell
MA100
17.616
Sell
MA200
14.123
Buy
Institutional Confidence
Currency: USD Updated: 2025-12-19The current institutional shareholding score of Seres Therapeutics Inc is 3.00, ranking 197/404 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 25.69%, representing a quarter-over-quarter decrease of 47.03%. The largest institutional shareholder is The Vanguard, holding a total of 311.89K shares, representing 3.45% of shares outstanding, with 1.16% decrease in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
Flagship Ventures
Nestle SA
Marshall Wace LLP
BlackRock Institutional Trust Company, N.A.
Bank Vontobel AG
Geode Capital Management, L.L.C.
Charles Schwab Investment Management, Inc.
State Street Investment Management (US)
1
2
Risk Assessment
Currency: USD Updated: 2025-12-19The current risk assessment score of Seres Therapeutics Inc is 2.55, ranking 229/404 in the Biotechnology & Medical Research industry. The company's beta value is 0.24. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.
Score
Beta vs S&P 500 index
0.23
VaR
+8.14%
240-Day Maximum Drawdown
+62.86%
240-Day Volatility
+114.88%
Return
Best Daily Return
60 days
+29.89%
120 days
+29.89%
5 years
+39.43%
Worst Daily Return
60 days
-24.21%
120 days
-24.21%
5 years
-61.83%
Sharpe Ratio
60 days
-0.37
120 days
+1.11
5 years
-0.12
Risk Assessment
Maximum Drawdown
240 days
+62.86%
3 years
+94.83%
5 years
+98.61%
Return-to-Drawdown Ratio
240 days
-0.28
3 years
-0.30
5 years
-0.20
Skewness
240 days
+0.35
3 years
+0.19
5 years
-0.37
Volatility
Realised Volatility
240 days
+114.88%
5 years
+110.79%
Standardised True Range
240 days
+9.25%
5 years
+48.15%
Downside Risk-Adjusted Return
120 days
+171.49%
240 days
+171.49%
Maximum Daily Upside Volatility
60 days
+84.92%
Maximum Daily Downside Volatility
60 days
+104.46%
Liquidity
Average Turnover Rate
60 days
+28.71%
120 days
+68.20%
5 years
--
Turnover Deviation
20 days
-51.55%
60 days
-50.11%
120 days
+18.54%
Peer Comparison
Biotechnology & Medical Research
Seres Therapeutics Inc
MCRB
6.02 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Amicus Therapeutics Inc
FOLD
8.80 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
KRYS
8.42 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Charles River Laboratories International Inc
CRL
8.41 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Madrigal Pharmaceuticals Inc
MDGL
8.35 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQV
8.30 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
FAQs
How does TradingKey generate the Stock Score of Seres Therapeutics Inc?
The TradingKey Stock Score provides a comprehensive assessment of Seres Therapeutics Inc based on 34 indicators derived from over 100 underlying data points. These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Seres Therapeutics Inc’s performance and outlook.
How do we generate the financial health score of Seres Therapeutics Inc?
To generate the financial health score of Seres Therapeutics Inc, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns. By integrating these comprehensive data, the financial health score not only reflects Seres Therapeutics Inc's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Seres Therapeutics Inc.
How do we generate the company valuation score of Seres Therapeutics Inc?
To generate the company valuation score of Seres Therapeutics Inc, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Seres Therapeutics Inc’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value. By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Seres Therapeutics Inc’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Seres Therapeutics Inc.
How do we generate the earnings forecast score of Seres Therapeutics Inc?
To calculate the earnings forecast score of Seres Therapeutics Inc, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.Comparing these indicators against peers provides context for the stock’s performance and helps
anchor more realistic expectations.These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Seres Therapeutics Inc’s future.
How do we generate the price momentum score of Seres Therapeutics Inc?
When generating the price momentum score for Seres Therapeutics Inc, we examine momentum indicators including support and resistance levels as well as volume metrics.Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.This comprehensive approach can reflect market sentiment and enable rational forecasts of Seres Therapeutics Inc’s prices. A higher score indicates a more stable short-term price trend for Seres Therapeutics Inc.
How do we generate the institutional confidence score of Seres Therapeutics Inc?
To generate the institutional confidence score of Seres Therapeutics Inc, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Seres Therapeutics Inc’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Seres Therapeutics Inc.
How do we generate the risk management score of Seres Therapeutics Inc?
To assess the risk management score of Seres Therapeutics Inc, we examine multiple key indicators related to returns, risk, volatility, and liquidity.The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.These indicators together provide a multi-dimensional understanding of Seres Therapeutics Inc’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Seres Therapeutics Inc.
